News

Emergency medicine physicians are leaving behind their emergency rooms and opening primary care practices, which does not necessarily translate to a smooth transition with some inherent challenges associated with training and expectations.

Many people who self-report as symptomatic for COVID-19 neglect to get tested, largely citing not knowing where to go for a test as the reason.

After an all-day meeting, the FDA’s Vaccine and Related Biological Products Advisory Committee (VRBPAC) voted 90% YES to recommend this fall’s COVID-19 booster doses target Omicron.

With the impending start to the 2022-2023 influenza season just a few months away, here is some information on what is being studied for vaccines as well as recommendations and new testing.

Algorithm offers guidance on clinically managing pregnant individuals exposed to monkeypox and on treating the virus during pregnancy.

Sanofi and GSK, Pfizer-BioNTech, and Moderna are all working on booster candidates specifically designed to neutralize Omicron and its subvariants.

The World Health Organization did not declare monkeypox a global health emergency, instead calling it an “evolving health threat” that requires continued monitoring.

The investigational therapy’s data points to a path towards a potential functional cure.

In a phase 3 trial, if HIV patients received treatment for precancerous HSILs, their risk for developing anal cancer was reduced by half.

Rochelle P. Walensky, MD, MPH, signs off on the Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices’ (ACIP) recommendation for individuals 6 through 17 years of age.

Dr. Heather Platt discusses the process of developing V116, a pneumococcal vaccine that targets the serotypes most prevalent in those 65 years and older.

The Centers for Disease Control and Prevention (CDC) is seeking more data on a possible cause of acute hepatitis in children, calling on clinicians to screen for adenovirus infections along with a broad range of possible exposures.

The federal agency says this is one of the worst outbreaks of this disease among these groups in US history, and has public health officials concerned as people gather during ongoing Pride Month activities.

This small study had 2 phases, but patients saw HIV viral suppression for about 40 weeks after receiving the combination therapy infusions.

Listen to our interview with Sanofi vaccine expert Dr. Christopher Rizzo about what this preferential recommendation means, and why high-dose flu vaccines are needed for older adults.

Patients with recurrent Clostridioides difficile infection saw improvements in fecal microbiome and bile acid after treatment with the investigational microbiota-based live biotherapeutic RBX2660.

Women who were taking hormone replacement therapy (HRT) for at least 6 months before COVID-19 infection had a 22% reduced risk of mortality.

Wearable health sensors predicted COVID-19 infection with up to 73% accuracy 2-10 days before symptom onset.

The company’s 15-valent conjugate shot becomes the first one that is approved in nearly a decade.

The largest genome sequence of S Typhi found strains of the bacteria are developing and spreading resistance to new antibiotics.

INSTIs have been thought to contribute to weight gain and metabolic syndrome, which in turn may contribute to cardiovascular events in HIV patients.

The stress of enduring an infectious disease pandemic expresses itself in a variety of mental health conditions, but the likelihood of experiencing particular symptoms depends on who you are.

Outpatients were frequently given systemic corticosteroids on the day of COVID-19 diagnosis, suggesting this usage should be further studied for safety and efficacy.

Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Carbapenem-resistant enterobacterales in Saudi Arabia were genotyped and the course of illness characterized to help inform treatment and prevention.

Studies, advances, and authorizations continue in this paramount area within infectious disease.

The CDC director endorsed the vote, and vaccines could be available to this young pediatric population by later this week.

This past week has been extremely busy in infectious disease with a lot of vaccine news that could impact young children. In addition, GSK reported on its phase 3 study on its RSV vaccine for seniors.

Using confirmed monkeypox cases in the Netherlands, investigators estimated the average time from infection to symptom onset was 8.5 days.

Following VRBPAC recommendations earlier this week, both the Pfizer-BioNTech and Moderna COVID-19 vaccines were FDA-authorized for children as young as 6 months.